Location of contact residues in pharmacologically distinct drug binding sites on P-glycoprotein

The multidrug resistance P-glycoprotein (P-gp) is characterised by the ability to bind and/or transport an astonishing array of drugs. This poly-specificity is imparted by at least four pharmacologically distinct binding sites within the transmembrane domain. Whether or not these sites are spatially...

Full description

Bibliographic Details
Main Authors: Mittra, Rituparna, Pavy, Megan, Subramanian, Nanditha, George, Anthony M., O'Mara, Megan L., Kerr, Ian D., Callaghan, Richard
Format: Article
Published: Elsevier 2017
Subjects:
Online Access:https://eprints.nottingham.ac.uk/40519/
_version_ 1848796076678578176
author Mittra, Rituparna
Pavy, Megan
Subramanian, Nanditha
George, Anthony M.
O'Mara, Megan L.
Kerr, Ian D.
Callaghan, Richard
author_facet Mittra, Rituparna
Pavy, Megan
Subramanian, Nanditha
George, Anthony M.
O'Mara, Megan L.
Kerr, Ian D.
Callaghan, Richard
author_sort Mittra, Rituparna
building Nottingham Research Data Repository
collection Online Access
description The multidrug resistance P-glycoprotein (P-gp) is characterised by the ability to bind and/or transport an astonishing array of drugs. This poly-specificity is imparted by at least four pharmacologically distinct binding sites within the transmembrane domain. Whether or not these sites are spatially distinct has remained unclear. Biochemical and structural investigations have implicated a central cavity as the likely location for the binding sites. In the present investigation, a number of contact residues that are involved in drug binding were identified through biochemical assays using purified, reconstituted P-gp. Drugs were selected to represent each of the four pharmacologically distinct sites. Contact residues important in rhodamine123 binding were identified in the central cavity of P-gp. However, contact residues for the binding of vinblastine, paclitaxel and nicardipine were located at the lipid-protein interface rather than the central cavity. A key residue (F978) within the central cavity is believed to be involved in coupling drug binding to nucleotide hydrolysis. Data observed in this investigation suggest the presence of spatially distinct drug binding sites connecting through to a single translocation pore in the central cavity.
first_indexed 2025-11-14T19:42:14Z
format Article
id nottingham-40519
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T19:42:14Z
publishDate 2017
publisher Elsevier
recordtype eprints
repository_type Digital Repository
spelling nottingham-405192020-05-04T18:23:07Z https://eprints.nottingham.ac.uk/40519/ Location of contact residues in pharmacologically distinct drug binding sites on P-glycoprotein Mittra, Rituparna Pavy, Megan Subramanian, Nanditha George, Anthony M. O'Mara, Megan L. Kerr, Ian D. Callaghan, Richard The multidrug resistance P-glycoprotein (P-gp) is characterised by the ability to bind and/or transport an astonishing array of drugs. This poly-specificity is imparted by at least four pharmacologically distinct binding sites within the transmembrane domain. Whether or not these sites are spatially distinct has remained unclear. Biochemical and structural investigations have implicated a central cavity as the likely location for the binding sites. In the present investigation, a number of contact residues that are involved in drug binding were identified through biochemical assays using purified, reconstituted P-gp. Drugs were selected to represent each of the four pharmacologically distinct sites. Contact residues important in rhodamine123 binding were identified in the central cavity of P-gp. However, contact residues for the binding of vinblastine, paclitaxel and nicardipine were located at the lipid-protein interface rather than the central cavity. A key residue (F978) within the central cavity is believed to be involved in coupling drug binding to nucleotide hydrolysis. Data observed in this investigation suggest the presence of spatially distinct drug binding sites connecting through to a single translocation pore in the central cavity. Elsevier 2017-01-01 Article PeerReviewed Mittra, Rituparna, Pavy, Megan, Subramanian, Nanditha, George, Anthony M., O'Mara, Megan L., Kerr, Ian D. and Callaghan, Richard (2017) Location of contact residues in pharmacologically distinct drug binding sites on P-glycoprotein. Biochemical Pharmacology, 123 . pp. 19-28. ISSN 0006-2952 P-glycoprotein; Multidrug resistance; Membrane transport; ABC protein; Cancer chemotherapy http://www.sciencedirect.com/science/article/pii/S000629521630346X doi:10.1016/j.bcp.2016.10.002 doi:10.1016/j.bcp.2016.10.002
spellingShingle P-glycoprotein; Multidrug resistance; Membrane transport; ABC protein; Cancer chemotherapy
Mittra, Rituparna
Pavy, Megan
Subramanian, Nanditha
George, Anthony M.
O'Mara, Megan L.
Kerr, Ian D.
Callaghan, Richard
Location of contact residues in pharmacologically distinct drug binding sites on P-glycoprotein
title Location of contact residues in pharmacologically distinct drug binding sites on P-glycoprotein
title_full Location of contact residues in pharmacologically distinct drug binding sites on P-glycoprotein
title_fullStr Location of contact residues in pharmacologically distinct drug binding sites on P-glycoprotein
title_full_unstemmed Location of contact residues in pharmacologically distinct drug binding sites on P-glycoprotein
title_short Location of contact residues in pharmacologically distinct drug binding sites on P-glycoprotein
title_sort location of contact residues in pharmacologically distinct drug binding sites on p-glycoprotein
topic P-glycoprotein; Multidrug resistance; Membrane transport; ABC protein; Cancer chemotherapy
url https://eprints.nottingham.ac.uk/40519/
https://eprints.nottingham.ac.uk/40519/
https://eprints.nottingham.ac.uk/40519/